Carcinoma of the Prostate
- 24 January 1991
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (4) , 236-245
- https://doi.org/10.1056/nejm199101243240406
Abstract
IN the 12 years since the topic was last reviewed in the Journal,1 prostatic cancer has become the most common newly diagnosed cancer in men. It is the cause of death in more than 28,000 men per year, accounting for 11 percent of cancer deaths, third in men after lung and colon cancer.2 Important questions remain about the cause and prevention of prostatic cancer, but new advances permit earlier diagnosis and more accurate staging. Curative therapy is possible for localized disease with much less morbidity than previously. In advanced disease, androgen-deprivation therapy remains the mainstay of treatment.Biology and . . .Keywords
This publication has 115 references indexed in Scilit:
- Isolation and properties of the FSH and LH-releasing hormonePublished by Elsevier ,2004
- ImpotenceNew England Journal of Medicine, 1989
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Prostate-Specific AntigenNew England Journal of Medicine, 1987
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Expression ofrasOncogene p21 in Prostate CancerNew England Journal of Medicine, 1986
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogenJournal of Steroid Biochemistry, 1983
- Prostatic CarcinomaNew England Journal of Medicine, 1979